Compare TR & TWST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TR | TWST |
|---|---|---|
| Founded | 1896 | 2013 |
| Country | United States | United States |
| Employees | 2300 | N/A |
| Industry | Specialty Foods | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.2B | 3.0B |
| IPO Year | N/A | 2018 |
| Metric | TR | TWST |
|---|---|---|
| Price | $42.42 | $43.32 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $48.75 |
| AVG Volume (30 Days) | 125.7K | ★ 1.1M |
| Earning Date | 01-01-0001 | 05-04-2026 |
| Dividend Yield | ★ 0.87% | N/A |
| EPS Growth | N/A | ★ 63.89 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $376,572,000.00 |
| Revenue This Year | N/A | $18.89 |
| Revenue Next Year | N/A | $15.28 |
| P/E Ratio | $32.36 | ★ N/A |
| Revenue Growth | N/A | ★ 20.32 |
| 52 Week Low | $29.13 | $23.30 |
| 52 Week High | $44.27 | $57.88 |
| Indicator | TR | TWST |
|---|---|---|
| Relative Strength Index (RSI) | 56.71 | 42.68 |
| Support Level | $41.55 | $42.89 |
| Resistance Level | $43.36 | $45.76 |
| Average True Range (ATR) | 1.29 | 2.64 |
| MACD | -0.22 | -0.90 |
| Stochastic Oscillator | 56.55 | 8.96 |
Tootsie Roll Industries Inc manufactures and sells confectionery products. Notable varieties include Tootsie Roll and Tootsie Pops, Charms, Blow-Pops, Dots, Junior Mints, Sugar Daddy and Sugar Babies, Andes, Dubble Bubble, Razzles among others. The company sells its products to wholesale distributors and directly to retail stores. Geographically, it generates a majority of its revenue from the United States and rest from Canada, Mexico and other regions.
Twist Bioscience Corp is a synthetic biology company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's proprietary semiconductor-based manufacturing process synthesizes DNA on silicon rather than traditional plastic plates, enabling the production of high-quality synthetic DNA faster, more affordably, and at scale. This platform overcomes conventional inefficiencies, supports cost-effective, high-throughput synthesis, and allows researchers to accelerate innovation. Geographically, the company operates across the Americas, EMEA, and APAC, deriving the majority of its revenue from the Americas.